The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Blood was tested for the presence of any remaining cancer cells using the clonoSEQ ... of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s human drugs advisory committee recommended approval of KTE-X19 (autologous anti-CD19-transduced CD3+ cells ...

that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ ® to include single time point testing to monitor for recurrence in ...

Bill Buryn knows his cancer will kill him one day. After years of chemo treatments and a stem cell transplant, his cancer ...